Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Theranexus publishes its cash position as of 30 june 2022

Lyon, France – 12 July 2022 – 6 pm CEST –  Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=4d0c5b6b32708f0543d895c3b29a2277
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS

Lyon, France – 9 June 2022– 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the

Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
  • · New milestone for NeuroLead, the active agent screening platform
  • · New publications in scientific journals
  • · Start of Phase I/II clinical trial for Batten disease

Lyon, 28 February 2022

THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS

Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE

Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022

Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has secured a €4.3

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Pulse Biosciences to Participate in the Stephens Annual Investment Conference: https://mms.businesswire.com/media/20211005005394/en/913083/5/pulse-logo.jpg
Pulse Biosciences to Participate in the Stephens Annual Investment Conference


Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to

Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum: https://mms.businesswire.com/media/20210728005556/en/894628/5/PAVmed_logo.jpg
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)

GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment


GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative

Pulse Biosciences Reports Third Quarter 2021 Financial Results: https://mms.businesswire.com/media/20211005005394/en/913083/5/pulse-logo.jpg
Pulse Biosciences Reports Third Quarter 2021 Financial Results


Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial

GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Sensorion to present in person at “Jefferies London Healthcare Conference” : https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion to present in person at “Jefferies London Healthcare Conference”


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021: https://mms.businesswire.com/media/20211005005394/en/913083/5/pulse-logo.jpg
Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021


Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third

Veris Health Showcased in PAVmed Digital Health Virtual Investor Event: https://mms.businesswire.com/media/20210728005556/en/894628/5/PAVmed_logo.jpg
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event


PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, hosted a virtual investor event with several

Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT

Lyon, 19 October 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces today that it will give an oral

Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)


Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Lucid Diagnostics Announces Pricing of Initial Public Offering: https://mms.businesswire.com/media/20210728005556/en/894628/5/PAVmed_logo.jpg
Lucid Diagnostics Announces Pricing of Initial Public Offering


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced